Tag:
pancreatic cancer
Latest Headlines
Latest Headlines
NuCana readies suite of PhIII cancer trials after rounding up mid-phase data
NuCana is set to start a Phase III trial of Acelarin in patients with pancreatic cancerthis month, kicking off a surge into late-stage studies that will see it work on ovarian and biliary programs later this year. The Sofinnova Ventures-backed biotech is initiating the multi-front advance on the strength of Phase I/II data, details of which were presented at ASCO.
Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx
Roche's Ventana struck a deal with Halozyme Therapeutics to develop a companion diagnostic test to use with Halozyme's new pancreatic cancer drug, adding to a recent string of collaborations as the company continues to expand its industry footprint.
Aduro swings for the fences with $119M IPO
Aduro Biotech is picking up in 2015 where it left off last year, riding momentum into an upsized $119 million IPO to fund its breakthrough pancreatic cancer immunotherapy combo CRS-207 and GVAX.
Aduro, BMS cancer vaccine combo to start Phase II
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.
UNC team uses electrical field to improve chemo delivery
Researchers at the University of North Carolina, Chapel Hill, have used electrical fields to deliver chemotherapy drugs to difficult tumors, and the small electrical charges have shown in animal tests to drive the therapies deep into solid tumors that were once hard to reach.
Michigan investigators finger ATDC gene for aggressive pancreatic cancer
Pancreatic cancer has long loomed as one of the most aggressive killers, typically leaving patients with a poor prognosis and specialists with few options for effective treatment. But now a team at the University of Michigan in Ann Arbor says they have new reason to believe that a particular gene is responsible for the fast-spreading cancer--offering a clear target for drug developers.
Gilead's oncology contender comes up short in pancreatic cancer
Gilead Sciences' simtuzumab failed to meet its main goal in a Phase II pancreatic cancer trial, denting the potential of a therapy the company hopes can treat a wide range of malignancies.
Aduro nabs FDA 'breakthrough' nod for pancreatic cancer vaccine combo
Aduro BioTech's GVAX, a previously failed cancer vaccine, is finding new life in a combination treatment that the Berkeley-based company is testing in patients with pancreatic cancer.
J&J partner Aduro grabs an FDA 'breakthrough' nod for its immuno-oncology combo
Aduro BioTech joined the short list companies outside Big Pharma to pick up the FDA's coveted breakthrough therapy designation, impressing the agency with strong mid-stage results for its combo cancer therapy.
Nanoliposome vehicles bring second-wave treatment for metastatic pancreatic cancer
Patients with pancreatic cancer whose disease still persists after regular treatments may benefit from a new cancer drug nanoliposome formulation, according to a presentation at the European Society for Molecular Oncology's 16th World Congress on Gastrointestinal Cancer.
